- UCB expects its full-year revenue to exceed €7 billion, compared to previous estimates of €6.5 billion to €6.7 billion.
- Adjusted EBITDA margin is anticipated to be at least 30%, given prior estimates of 29.4%.
- Core EPS is projected to be at least €7.25, with initial estimates ranging from €6.80 to €7.40.
- For the first half of the year, UCB achieved core EPS of €3.53, surpassing the estimate of €3.48.
- First half revenue reached €3.49 billion, exceeding the estimated €3.21 billion.
- Specific product sales include:
- Cimzia: €959.0 million, higher than the estimated €936.1 million.
- Vimpat: €178.0 million, above the estimated €134.6 million.
- Keppra: €221.0 million, below the estimated €262.5 million.
- Briviact: €377.0 million, slightly exceeding the estimate of €374.1 million.
- Neupro: €110.0 million, surpassing the estimate of €98.6 million.
- Evenity: €63 million, lower than the estimated €68.2 million.
- Bimzelx: €799 million, significantly higher than the estimated €611.7 million.
- Adjusted EBITDA for the first half was €1.03 billion, ahead of the expected €948.9 million.
- Gross profit reached €565 million, though notably lower than the estimated €2.34 billion.
- Looking ahead, UCB plans to launch a phase 3 program for fenfluramine in treating Rett syndrome, starting in the first half of 2026.
- Market feedback includes 16 buy ratings, 5 hold ratings, and 2 sell ratings.
A look at UCB SA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
UCB SA, a biopharmaceutical company specializing in the treatment of central nervous system disorders and inflammatory diseases, has been assigned Smart Scores indicating its long-term outlook. With a Growth score of 5 and a Resilience score of 4, UCB SA shows potential for significant long-term expansion and a strong ability to weather challenging market conditions. However, with Value, Dividend, and Momentum scores of 2 each, the company may face challenges in terms of its current valuation, dividend payouts, and market momentum.
UCB SA‘s high Growth and Resilience scores suggest a promising future for the company in the biopharmaceutical industry. Investors may view UCB SA as a growth-oriented investment opportunity due to its strong potential for development and ability to withstand market volatility. However, considerations should be made regarding the company’s current valuation, dividend policy, and momentum to make well-informed investment decisions moving forward.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
